References
- Bray F, Ferlay J, Soerjomataram I, et al (2018) Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. Cancer J Clin; 68:394–424.
doi:10.3322/caac.21492.
- Soukup V, Capoun O, Cohen D, et al (2020) Risk stratification tools
and prognostic models in non-muscle-invasive bladder cancer: a
critical assessment from the European Association of Urology
Non-Muscle-Invasive Bladder Cancer Guidelines Panel. Eur Urol Focus;
6:479-489. doi: 10.1016/j.euf.2018.11.005
- Smith S, Zaharoff D (2016) Future directions in bladder cancer
immunotherapy: towards adaptive immunity. Immunotherapy 8(3):351-65.
doi: 10.2217/imt.15.122.
- Van Rhijn BWG, Burger M, Lotan Y, et al (2009) Recurrence and
progression of disease in non–muscle-invasive bladder cancer: from
epidemiology to treatment strategy. Eur Urol; 56:430-442. doi:
10.1016/j.eururo.2009.06.028.
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next
generation. Cell 144: 646–674. doi: 10.1016/j.cell.2011.02.013.
- Wiker HG, Harboe Ö (1992) The antigen 85 complex: a major secretion
product of Mycobacterium tuberculosis. Microbiological Reviews
56:648-661.
- Dowell AC, Cobby E, Wen K, et al (2017) Interleukin-17-positive mast
cells influence outcomes from BCG for patients with CIS: Data from a
comprehensive characterisation of the immune microenvironment of
urothelial bladder cancer. PLoS ONE 12(9): e0184841. doi:
10.1371/journal.
- Awad JA, Morrow JD, Roberts LJ (1994) Detection of the major urinary
metabolite of prostaglandin D2 in the circulation: demonstration of
elevated levels in patients with disorders of systemic mast cell
activation. J Allergy Clin Immunol 93:817-824. doi:
10.1016/0091-6749(94)90371-9.
- Valent P, Akin C, Arock M, et al (2012) Definitions, criteria and
global classification of mast cell disorders with special reference to
mast cell activation syndromes: a consensus proposal. Int Arch Allergy
Immunol 157:215-25. doi: 10.1159/000328760.
- Lamm DL, Blumenstein BA, Crissman JD, et al (2000) Maintenance
bacillus Calmette-Gue ̵́ rin immunotherapy for recurrent Ta, T1 and
carcinoma in situ transitional cell carcinoma of the bladder: a
randomized Southwest Oncology Group Study. J Urol 163:1124–9. doi:
10.1016/S0022- 5347(05)67707-5.
- Kassouf W, Traboulsi SL, Dräger BS, et al (2016) Follow-up in
non–muscle-invasive bladder cancer- International Bladder Cancer
Network recommendations. Urol Oncol 34:460-8. doi:
10.1016/j.urolonc.2016.05.028.
- Watanabe E, Matsuyama H, Matsuda K, et al (2007) Urinary interleukin-2
may predict clinical outcome of intravesical bacillus Calmette-Gue ̵́rin
immunotherapy for carcinoma in situ of the bladder. International
Journal of Urology 14:140–146. doi: 10.1007/s00262-003-0384-9.
- Kamat AM, Orten S. (2014): Myths and mysteries surrounding Bacillus
Calmette- Gue´rin therapy for bladder cancer. Eur Urol 65:267–269.
doi: 10.1016/j.eururo.2013.10.016.
- Biot C, Rentsch CA, Gsponer JR, et al (2012) Preexisting BCG-specific
T cells improve intravesical immunotherapy for bladder cancer. Sci
Transl Med 4:137-172. doi: 10.1126/scitranslmed.3003586.
- Parviainen S, Ahonen M, Diaconu I, et al (2014) CD40 ligand and
tdtomato-armed vaccinia virus for induction of antitumor immune
response and tumor imaging. Gene Ther 21:195-204. doi:
10.1038/gt.2013.73.
- Rosser CJ, Dai Y, Miyake M, et al (2014) Simultaneous multi- analyte
urinary protein assay for bladder cancer detection. BMC Biotechnol
14:424. doi: 10.1186/1472-6750-14-24.
- Kanematsu A, Inoue T, Iwamura H, et al (1998) Intravesical bacillus
Calmette-Guerin instillation for patients over 80 years old. Acta
Urologica Japonica 44:253-257.
- Joudi FN, Smith BJ, O’Donnell MA, et al (2006) The impact of age on
the response of patients with superficial bladder cancer to
intravesical immunotherapy. J Urol 175:1634-1640. doi:
10.1016/S0022-5347(05)00973-0.
- Fernandez J, Solsona E, Unda M, et al (2008) Prognostic factors in
patients with non-muscle-invasive bladder cancer treated with bacillus
Calmette-Guerin: multivariate analysis of data from four randomized
CUETO trials. Eur Urol 53:992-1001. doi: 10.1016/j.eururo.2007.10.006.